Sosei Group (JP:4565) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Nxera Pharma reports positive Phase 2 results for NBI-1117568, a potential new once-daily oral treatment for schizophrenia showing significant symptom improvement. Developed in partnership with Neurocrine Biosciences, the drug met primary and secondary endpoints with good safety and tolerability. This success paves the way for Phase 3 trials and highlights the strength of Nxera’s NxWave discovery platform in addressing complex neurological disorders.
For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.
